The stand-alone Ayurveda treatment for the management of COVID-associated mucormycosis (CAM): a case report - Takeaways - MDSpire

The stand-alone Ayurveda treatment for the management of COVID-associated mucormycosis (CAM): a case report

  • By

  • Rajnikant Patel

  • Skanthesh Lakshmanan

  • Vinayak Padikkal

  • Keyur Mandaliya

  • June 5, 2026

  • 0 min

Share

  • 1

    Mucormycosis is a rapidly progressive fungal infection primarily affecting immunocompromised individuals and those with diabetes.

  • 2

    This case study presents a 60-year-old male with COVID-19 who developed invasive mucormycosis managed exclusively with Ayurveda.

  • 3

    Diagnostic evaluation confirmed mucormycosis through potassium hydroxide testing, histopathology, and fungal culture.

  • 4

    The patient showed progressive symptomatic improvement with Ayurveda treatment over 90 days and no adverse events reported.

  • 5

    At three-year follow-up, there was no clinical recurrence, and laboratory parameters remained normal.

Original Source(s)

The stand-alone Ayurveda treatment for the management of COVID-associated mucormycosis (CAM): a case report

  • by Rajnikant Patel, Skanthesh Lakshmanan, Vinayak Padikkal, Keyur Mandaliya

  • June 5, 2026

Related Content

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

COVID-19 Vaccination in Pregnancy: Efficacy of Second-Generation Vaccines, Maternal-Neonatal Safety, and Strategies to Address Vaccine Hesitancy

Acute liver failure and secondary TMA-like phenomenon following SARS-CoV-2 and Mycoplasma pneumoniae co-detection in a child: a case report